---
document_datetime: 2024-09-30 11:43:24
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/zercepac-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: zercepac-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.7752643
conversion_datetime: 2025-12-15 02:17:02.812654
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Zercepac

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                             | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0036/G            | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a | 27/09/2024                          |                                             | SmPC and Labelling               |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | medicinal product - Change in the manufacturer of AS or of a material/reagent/intermediate for AS - New site of MCB and/or WCB                                                                                                                                                                                                                                                                                                                                                                                               |            |     |    | biological/immunological B.I.a.1.k starting storage   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|-------------------------------------------------------|
| IA/0037   | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a                                                                                                                                                                                                                                                                                                                     | 07/08/2024 | n/a |    | Member State                                          |
| N/0035    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/07/2024 |     | PL |                                                       |
| IB/0033   | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                                                                                | 21/06/2024 | n/a |    |                                                       |
| IA/0034/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or a novel excipient | 04/06/2024 | n/a |    | manufacturer of                                       |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                               | 07/12/2023   | n/a   |          | IB/0032             |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|----------|---------------------|
| IB/0031/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation       | 10/11/2023   | n/a   |          |                     |
| IB/0030/G | This was an application for a group of variations. B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.I.a.3.z - Change in batch size (including batch size ranges) of AS or intermediate - Other variation                            | 12/09/2023   | n/a   |          |                     |
| II/0021   | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes | 31/08/2023   | n/a   |          |                     |
| IA/0029   | A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                          | 10/07/2023   |       | Annex II | manufacturing sites |

<div style=\"page-break-after: always\"></div>

| IB/0028/G   | This was an application for a group of variations. B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved                                                                                                                                                                                                           | 04/07/2023   | n/a   |      | stability protocol   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|------|----------------------|
| IB/0027     | B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition                                                                                                                                                                                                                                                                                                                                                            | 16/05/2023   | n/a   |      |                      |
| IB/0026     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                                                                                                | 17/03/2023   | n/a   |      |                      |
| IA/0025     | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                | 07/02/2023   |       | SmPC |                      |
| II/0022     | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                                                                                       | 19/01/2023   | n/a   |      |                      |
| II/0020     | Submission of the final report from study HLX02- BC01 in order to fulfil REC/006. This is a double- blind, randomised, parallel-controlled, multicentre, international, phase 3 study to compare the efficacy, safety, and immunogenicity of HLX02 versus EU- sourced Herceptin in combination with docetaxel. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority | 12/01/2023   | n/a   |      |                      |

<div style=\"page-break-after: always\"></div>

| IA/0024            | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                          | 16/12/2022   | n/a   |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------|
| IAIN/0023          | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                  | 16/12/2022   | n/a   |                                   |
| II/0016            | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes  | 24/11/2022   | n/a   |                                   |
| PSUSA/3010/ 202109 | Periodic Safety Update EU Single assessment - trastuzumab                                                                                                                                                                                                                                           | 10/06/2022   | n/a   | PRAC Recommendation - maintenance |
| IB/0019/G          | This was an application for a group of variations. B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.e.z - Change in container closure system of the Finished Product - Other variation | 07/04/2022   | n/a   |                                   |
| IB/0018            | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting                                                                                                              | 04/02/2022   | n/a   |                                   |

<div style=\"page-break-after: always\"></div>

|           | material/intermediate                                                                                                                                                                                                                                                                                                                                                                             |            |            |             |                         |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------|
| II/0015/G | for a group of variations. B.I.c.1.b - Change in immediate packaging of the AS - Qualitative and/or quantitative composition for sterile and non-frozen biological/immunological ASs B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 13/01/2022 | n/a        |             | This was an application |
| II/0013/G | This was an application for a group of variations. B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product | 11/11/2021 | 31/10/2022 | Annex II    |                         |
| IB/0014   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                      | 28/10/2021 | 15/11/2021 | SmPC and PL |                         |
| IB/0012/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                | 17/09/2021 | n/a        |             |                         |

<div style=\"page-break-after: always\"></div>

|             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                                                  |            |            |                        |                                                                                                                                             |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0011     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                               | 09/08/2021 | 15/11/2021 | SmPC and PL            | To update sections 4.6, 6.6 of the SmPC to update the safety information following assessment of the same change for the reference product. |
| IAIN/0010/G | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) | 14/07/2021 | 15/11/2021 | Annex II and PL        |                                                                                                                                             |
| II/0008     | B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products                                                                                                                                                                                                                                                   | 20/05/2021 | 15/11/2021 | SmPC, Labelling and PL |                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

| IB/0006   | - Change in the manufacturing process of finished or intermediate product - Minor change the manufacturing process                                                                                                                                                                                                                                                                             | 15/02/2021   | n/a        |                        | B.II.b.3.a the in   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------------|
| II/0003   | B.II.e.5.c - Change in pack size of the finished product - Change in the fill weight/fill volume of sterile multidose (or single-dose, partial use) parenteral medicinal products, including biological/immunological medicinal products                                                                                                                                                       | 11/02/2021   | 15/11/2021 | SmPC, Labelling and PL |                     |
| IB/0009/G | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process    | 29/01/2021   | n/a        |                        | of the AS           |
| IB/0007/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.z - Change in the manufacturer of AS or of a material/reagent/intermediate for AS - Other | 27/01/2021   | n/a        |                        | starting            |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             | variation   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------|
| IB/0005   | B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                                                                                                                                                                         | 27/01/2021 | 15/11/2021 | SmPC and PL |             |
| IB/0004   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                  | 04/12/2020 | 15/11/2021 | SmPC and PL |             |
| IB/0002   | B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                          | 25/11/2020 | n/a        |             |             |
| IB/0001/G | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol | 06/11/2020 | 15/11/2021 | SmPC        |             |